Changes to Primary End Points in Randomized Clinical Trials on Immune Checkpoint Inhibitors in Urothelial, Renal Cell, and Lung Cancers: A Systematic Review

H. Yildirim

Changes to Primary End Points in Randomized Clinical Trials on Immune Checkpoint Inhibitors in Urothelial, Renal Cell, and Lung Cancers: A Systematic Review

Research output: Contribution to journal › Article › Academic › peer-review

Original language	English
Pages (from-to)	1144-1147
Journal	JAMA Oncology
Volume	9
Issue number	8
Publication status	Published - 1 Aug 2023

Cite this

@article{5e8b41a93681471e92c0176308bada52,

title = "Changes to Primary End Points in Randomized Clinical Trials on Immune Checkpoint Inhibitors in Urothelial, Renal Cell, and Lung Cancers: A Systematic Review",

author = "H. Yildirim",

year = "2023",

month = aug,

day = "1",

language = "English",

volume = "9",

pages = "1144--1147",

journal = "JAMA Oncology",

issn = "2374-2437",

publisher = "American Medical Association",

number = "8",

}